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Group A, B, and D, 200 µg for Group C) and were monitored for 
144 hours (Group A, B, and C) or 72 hours (Group D). PK samples 
were analyzed by liquid chromatography coupled to tandem mass 
spectrometry. PK parameters of selexipag and ACT-333679 were 
explored using ratios of geometric means and their 90% CIs.
Results: PK results (geometric mean (95% CI)) are presented in the 
table below:
The free fraction of both compounds in plasma increased only in 
Group B (30%). Group C PK data are not included here (2 subjects 
only). Selexipag 400 µg was generally well tolerated in all groups. 
Ten subjects reported 14 adverse events: 4, 6, 2, and 2 in Group 
A, B, C, and D, respectively. One serious adverse event (hepatic 
encephalopathy) occurred in Group C, in the context of urinary 
infection and previous history of encephalopathy. No clinically 
relevant changes in clinical laboratory variables and electrocardio-
grams were observed.
Conclusion: Selexipag exposure increased in subjects with mild or 
moderate liver impairment compared with healthy subjects whereas 
exposure to ACT-333679 remained unchanged in subjects with mild 
liver impairment and doubled in subjects with moderate liver impair-
ment. No conclusion could be drawn for severe liver impairment.
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Introduction: Azole antifungal drugs display a nonlinear pharma-
cokinetic profile and present pharmacokinetics/pharmacodynamic 
relationships that is the reason why therapeutic drug monitoring is 
highly recommended. In time, we observed that cystic fibrosis lung 
transplant patients show an extensive metabolism and that dose esca-
lation, without reducing time between dose intervals, cannot lead to 
reach optimal blood level. The objective of this work is to evaluate 
the administration of voriconazole 3 times daily to reach the thera-
peutic range (1–4.5 mg/L) in this population.
Patients (or Materials) and Methods: A retrospective study was car-
ried out on cystic fibrosis lung transplant patients. Inclusion criteria 
were as follow: intravenous administration of voriconazole twice 
daily with a trough concentration < 0.5 mg/L, and then dose adjust-
ment from twice to 3 times daily. Trough concentration was com-
pared before and after dose adjustment. A validated high-pressure 
liquid-chromatography tandem mass spectrometry assay was used 
to determine voriconazole concentrations
Results: Seven cystic fibrosis patients have been included (4 males, 
3 females)
After dose adjustment from twice to 3 times daily, trough con-
centrations for 6 patients were in the therapeutic range. Only 1 was 
under 1 mg/L.
Conclusion: In this population of patients, recommended twice daily 
dose of 6 mg/kg for the first 24 hours followed by 4 mg/kg cannot 
lead to trough concentration of 1 mg/L. This adjustment from twice 
daily to 3 times daily could be a good method to reach the thera-
peutic range. Nonetheless, more studies should be planed concern-
ing efficacy and tolerance. These data illustrate also the nonlinear 
pharmacokinetic of voriconazole: from 6.5 mg/kg × 2 per day to 7.4 
mg/kg × 3 per day, trough concentrations display a 10-fold increase.
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Introduction: Psoriasis is a common chronic inflammatory skin dis-
ease, which has long been recognized to be associated with depression, 
among other comorbidities. Venlafaxine (VLX), a racemic mixture 
of (S)-(+) and (R)-(-) enantiomers indicated for the treatment of 
depressive illness, is metabolized to O-desmethylvenlafaxine (ODV), 
N-desmethylvenlafaxine (NDV) and N,O-didesmethylvenlafaxine 
(NODV). Considering that inflammatory disease states have been 
associated with down-regulation of drug-metabolizing enzymes 
and transporters in the liver and considering that in psoriasis many 
CYP in skin are induced, the present study evaluates the influence 
of psoriasis on kinetic disposition and metabolism of venlafaxine 
enantiomers.
Patients (or Materials) and Methods: Patients with psoriasis (n = 
12) and healthy volunteers (n = 11) were treated with a single oral 
dose of racemic venlafaxine (150 mg). Serial blood samples were col-
lected up to 48 hours after drug administration. Venlafaxine and its 
metabolites enantiomers were analyzed in plasma samples by LC-MS/
MS coupled with a chiral column Chirobiotic V. Pharmacokinetics 
parameters were evaluated using the WinNonlin software.
Results: Compared with healthy subjects who were similar overall in 
terms of age, sex, and body mass index (BMI), the means area under 
the plasma concentration-time curve from time zero extrapolated to 
infinity (AUC0-∞) for venlafaxine and its metabolites enantiomers did 
not differ (unpaired t test) in patients with psoriasis. The following 
Group A Group B Group D
Parameter Selexipag ACT-333679 Selexipag ACT-333679 Selexipag ACT-333679
Cmax1 
[ng/mL]
3.9 (2.8–
5.3)
4.5 (3.1–
6.7)
5.4 (3.9–
7.3)
5.3 (4.6–
6.0)
1.9 (1.5–
2.4)
3.8 (3.0–
5.0)
tmax2 [h] 1.0 (1.0–
4.0)
5.0 (3.0–
6.0)
2.0 (1.0–
6.0)
6.0 (4.0–
7.0)
1.0 (1.0–
2.0)
4.0 (4.0–
6.0)
t1/23 [h] 1.6 (1.3–
2.1)
6.5 (4.9–
8.6)
2.2 (1.6–
3.0)
15.9 
(10.1–
25.0)
1.1 (0.8–
1.4)
12.6 (9.1–
17.5)
AUC0-∞4 
[ng*h/
mL]
10.9 
(8.6–
13.8)
29.6 
(20.6–
42.6)
23.5 
(17.0–
32.4)
56.1 
(42.8–
73.5)
5.3 (4.5–
6.2)
25.3 
(21.9–
29.3)
1peak concentration; 2time to reach Cmax, median (range); 3terminal half-life, 4expo-
sure from 0 to ∞.
n 7
age (years) 24.7 (5.44) [21–32]
weight (kg) 48,8 ± 4,95 [44–56)]
time posttransplant (days) 22,8 ± 27,13 [8.5–83.5]
Before dose adjustment After dose adjustment
Trough concentration (mg/L) 0.25 (0.15) [0.03–0.52] 2.26 (1.10) [0.68–4]
Voriconazole dose (mg/kg) 6,47±2,12 [4–9.2 ) × 2/d 7.35 (1.52) [5.36–9,17] × 3/d
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AUC0–∞ values were obtained, respectively, for patients with psoriasis 
and healthy volunteers: (S)-(+)-VLX, 729.7 vs 647.9 ng·h/mL; (R)-(-)-
VLX, 532.0 vs 327.6 ng·h/mL; (S)-(+)-ODV, 2742.7 vs 2463.1 ng·h/
mL; (R)-(-)-ODV, 2977.0 vs 2603.6 ng·h/mL; (S)-(+)-NDV, 281.7 vs 
60.8 ng·h/mL; (R)-(-)-NDV, 507.2 vs 192.3 ng·h/mL; (S)-(+)-DDV, 
758.6 vs 585.5 ng·h/mL; and (R)-(-)-DDV, 563.5 vs 482.9 ng·h/mL.
Conclusion: Psoriasis did not alter the kinetic disposition and metab-
olism of venlafaxine enantiomers following a single oral administra-
tion of the racemic drug.
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Introduction: Critically ill patients may display altered pharmacoki-
netic parameters. Therapeutic drug monitoring (TDM) is essential 
to optimize the use of antibiotics in intensive care units. Many TDM 
assessments may be inappropriate as a result of improper interpreta-
tion or collection timing. We assessed the practice of TDM of vanco-
mycin and aminoglycosides in an adult intensive care unit.
Patients (or Materials) and Methods: We performed a retrospective 
analysis of all vancomycin and aminoglycosides plasma level deter-
minations performed between January 1, 2011, and December 31, 
2011, in adult patients admitted in the intensive care unit of Geneva 
University Hospitals, Switzerland.
Results: A total of 845 antibiotic plasma levels were performed 
in 193 patients, among which 773 levels could be interpreted. The 
majority of TDM were related to vancomycin (87%), while amino-
glycoside TDM were less frequent (13%). For intermittent vanco-
mycin, the dosage was not changed in 27% of high through levels 
and 23% of low through levels. A dosage increase was observed in 
only 22% of low through levels. Moreover, about one half of the 
samples were drawn too early. For continuous vancomycin, dosage 
was not changed in 17% of high plasma levels and 33% of low levels. 
A dosage increase was observed in only 30% of low levels. About 
60% of the samples were drawn too early. For aminoglycosides, the 
dosage was not changed in 20 to 30% of the cases when high through 
levels were measured. As for vancomycin, samples were frequently 
drawn too early.
Conclusion: Our results show that the practice of TDM of vanco-
mycin and aminoglycosides could be improved. Too high or too low 
levels did not systematically result in dosage changes and samples 
were frequently drawn too early.
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Introduction: In critically ill patients with hospital-acquired pneu-
monia, pathophysiologic changes alter the pharmacokinetics of 
antibiotics. Imipenem exhibits primarily time-dependent killing. Its 
administration by prolonging the intermittent infusion may increase 
time with serum concentrations above the minimum inhibitory con-
centration of the suspected pathogens (t > MIC).
Patients (or Materials) and Methods: Inclusion criteria were hos-
pital-acquired pneumonia, treatment by imipenem/cilastatin, and 
expected continuation of mechanic ventilation for at least 48 hours 
from the recruitment into the trial. Enrolled patients were randomly 
divided into either bolus group (to receive 1-g imipenem over 30 
minutes every 8 hours) or extended group (0.5 g administered over 
3 hours every 6 hours). Imipenem plasma concentrations were deter-
mined by reversed-phase HPLC during the second day of imipenem 
treatment. Pharmacokinetic data were determined using a 1-compart-
ment model. The target pharmacokinetic/pharmacodynamic param-
eter, percentage of dosing interval in which plasma concentration of 
imipenem exceeded 4 times the minimum inhibitory concentration 
(%t > 4 × MIC), was assessed using individual concentration–time 
curves for MIC of 0.5, 1, and 2 mg/L. Kolmogorov-Smirnov test was 
used to confirm normal distribution of data, which were then tested 
by unpaired t test.
Results: Twenty-two patients entered this study. Patients in both 
groups were matched with regard to other demographic data, renal 
functions, and severity of illness. The parameter % t > 4 × MIC was 
comparable in both groups for MIC of 0.5 mg/L, ranging from 74% 
to 100% in bolus group and from 55% to 100% in extended group. 
For MIC of 1 mg/L, the difference in both groups was not statistically 
significant, ranging from 59% to 100% in bolus group and from 
31% to 100% in extended group. However, in the extended group, 
in 2 patients (20%) imipenem concentration in plasma did not remain 
above 4 × MIC for 40 % of the dosing interval. All patients in the 
bolus group achieved the PK/PD target for MIC of 2 mg/L. In the 
extended group, majority of the patients did not achieve this target. 
On the other hand, imipenem plasma concentration was above 4 × 
MIC of 2 mg/L for more than 90% of the dosing interval in 1 patient 
in extended group.
Conclusion: In artificially ventilated patients with hospital-acquired 
pneumonia, prolonged infusion of imipenem/cilastatin to 3 hours 
(with reduced total daily dose) does not lead to an improvement of 
the main tested PK/PD parameter - time upon the 4 times suspected 
pathogen’s MIC.
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Introduction: Darunavir (DRV), a protease inhibitor, potently sup-
presses the replication of wild-type and drug-resistant HIV-1, but 
its clinical efficacy varies greatly among individuals. Recently, the 
importance of the concentrations of DRV in blood cells, the site of 
action for DRV, has been focused. In this study, we assessed the influ-
ence of plasma and intracellular concentration of DRV on its clinical 
efficacy. The factors acting for the intracellular concentration of DRV 
is also investigated.
